Monthly Archives: August 2018

Top 10 Biotech Stocks To Buy For 2019

Alexion Pharmaceuticals (ALXN) jumped to the top of the S&P 500 today after Barclays upgraded the biotech stock to Overweight from Equal Weight citing fewer macro headwinds.

Getty Images

Shares of Alexion Pharmaceuticals gained 5.2% to $125.59, while the S&P 500 rose 0.1%.

Barclays analyst Geoff Meacham and team explain why they upgraded Alexion Pharmaceuticals:

We are upgrading shares ofAlexion to Overweight and increasing our PT to $155 from $150 on an improved outlook for 2017. Specifically, we see lower FX and fewer macroeconomic risks to the core base business over the next 12 months. We also expect approval of Soliris in refractory gMG by YE17 following a planned regulatory submission in 1Q17, which could add another growth lever in early 2018 at the latest. Our upgrade is not a call on the recent 10-Q delay, which according to our discussions with management has to do with an investigation into sales practices following allegations by a former employee. We also do not anticipate major restatements of historical Soliris sales due to the investigation. Furthermore, this is not a call on Kanuma or the Synageva deal, as we have cut our Kanuma sales in our P&L and reduced its contribution in our NPV valuation. Indeed, we would expect minimal weakness inAlexion shares if the company were to take a write-down on Synageva during 2017, but this is not core to our investment thesis. In sum, our bullishness onAlexion shares is due to: 1) lessened FX and macroeconomic headwinds in 2017, 2) near-term Soliris growth from likely regulatory approval in refractory gMG, and 3) attractive upside potential from current levels as the pipeline including line extensions for Soliris and new assets such as 1210 mature.

Top 10 Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Joseph Griffin]

    BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

  • [By Shane Hupp]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by equities research analysts at Morgan Stanley from $107.00 to $99.00 in a report released on Friday. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 3.97% from the stock’s current price.

  • [By Keith Speights]

    It’s not exactly David vs. Goliath. However, Bellicum Pharmaceuticals (NASDAQ:BLCM) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are definitely in different leagues right now. Both are clinical-stage biotechs, but Bellicum’s market cap is less than $350 million while Alnylam’s market cap is close to $10 billion.

  • [By Keith Speights]

    Speaking of competition, Ionis should have its hands full battling rivals for Tegsedi assuming the drug wins approval. Alnylam (NASDAQ:ALNY) anticipates winning FDA approval for its hATTR drug patisiran within a few weeks. Because the FDA delayed its decision on Tegsedi, Alnylam appears to be in position to reach the market first. In addition to its first-mover advantage, patisiranappears to have an edge over Tegsedi in efficacy and safety based on clinical data for the two drugs.

Top 10 Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Private Capital Group LLC boosted its stake in Amgen, Inc. (NASDAQ:AMGN) by 1,703.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,362 shares of the medical research company’s stock after purchasing an additional 2,231 shares during the period. Private Capital Group LLC’s holdings in Amgen were worth $403,000 at the end of the most recent reporting period.

  • [By Cory Renauer]

    Patient Amgen Inc.(NASDAQ:AMGN) shareholders have seen the stock quadruple in price over the past decade, plus they’ve enjoyed one of the fastest-growing dividends in biopharma. Now that the company’s launched a new migraine headache drug, investors are wondering if the former highflier can put on another memorable performance.

  • [By Shane Hupp]

    Investors sold shares of Amgen, Inc. (NASDAQ:AMGN) on strength during trading hours on Thursday. $63.15 million flowed into the stock on the tick-up and $134.51 million flowed out of the stock on the tick-down, for a money net flow of $71.36 million out of the stock. Of all stocks tracked, Amgen had the 0th highest net out-flow for the day. Amgen traded up $2.11 for the day and closed at $185.79

  • [By Chris Lange]

    Amgen Inc. (NASDAQ: AMGN) is expected to release its most recent quarterly results on Thursday. The consensus forecast calls for $3.54 in EPS and $5.74 billion in revenue for the second quarter. Shares traded on Fridays close at $190.60. The consensus price target is $196.10, and the 52-week range is $163.31 to $201.23.

Top 10 Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Woodford Investment Management LLP’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP

    These are the top 5 holdings of Woodford Investment Management LLPProthena Corp PLC (PRTA) – 11,557,614 shares, 37.95% of the total portfolio. Shares added by 0.25%Alkermes PLC (ALKS) – 5,270,428 shares, 27.32% of the total portfolio. Shares reduced by 30.52%Theravance Biopharma Inc (TBPH) – 10,898,879 shares, 23.64% of the total portfolio. Shares added by 1.41%Biogen Inc (BIIB) – 279,564 shares, 6.85% of the total portfolio. Shares reduced by 24.56%Evofem Biosciences Inc (EVFM) – 7,465,538

  • [By Cory Renauer]

    There’s a lot for investors to like aboutAmgen Inc. (NASDAQ:AMGN) andBiogen Inc. (NASDAQ:BIIB). Both of these biotech stocks have produced tremendous returns over the past couple of decades, and the businesses they represent still generate enormous profits.

  • [By Chris Lange]

    Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage gain ahead of the close was Biogen Inc. (NASDAQ: BIIB) which traded up about 19% at $355.17. The stocks 52-week range is $249.17 to $370.57. Volume was over 12 million compared to the daily average volume of 1.6 million.

  • [By Todd Campbell]

    Drugmakers’ dustbins are filled with failed attempts to slow the progression of Alzheimer’s disease, yet drug developers, includingBiogen(NASDAQ:BIIB), remain undaunted in their pursuit of new treatments. Recently, Biogen reported data from a midstage trial that suggests it could be rewarded for its perseverance. In hundreds of patients, the company’s BAN2401 successfully slowed disease progression as measured by the Alzheimer’s Disease Composite Score (ADCOMS). Is this the breakthrough patients have been waiting for?

Top 10 Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of ArQule (NASDAQ:ARQL) from a hold rating to a buy rating in a report released on Saturday.

    A number of other research firms have also issued reports on ARQL. Roth Capital upped their price target on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Zacks Investment Research lowered ArQule from a buy rating to a hold rating in a research report on Wednesday, April 4th. ValuEngine upgraded ArQule from a hold rating to a buy rating in a research report on Wednesday, May 2nd. Finally, B. Riley set a $4.00 price target on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Seven analysts have rated the stock with a buy rating, The stock currently has an average rating of Buy and an average target price of $4.69.

  • [By Lisa Levin] Gainers
    Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
    Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
    Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
    Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
    Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
    ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
    Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
    Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
    ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
    Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
    Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
    Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
    Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
    Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
    Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
    Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

    Check out these big penny stock gainers and losers

  • [By Ethan Ryder]

    ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

  • [By Joseph Griffin]

    Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.

  • [By Joseph Griffin]

    ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

    Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

Actively managed blockchain ETF joins suddenly crowded field

A new blockchain exchange-traded fund launched Wednesday on the New York Stock Exchange.

The REX BKCM ETF (BKC) holds shares of 32 companies working in cryptocurrencies or their underlying blockchain technology. The ETF is run by Rex Shares and actively managed by Brian Kelly, a CNBC contributor and head of BKCM, which runs a digital assets strategy for clients.

BKC traded little changed Wednesday morning near $25.14 a share. As of launch, the ETF’s five largest holdings were: Taiwan Semiconductor Manufacturing, Global Unichip, GMO Internet, Overstock.com and SVB Financial Group. Each had an 8 percent weighting in the ETF.

show chapters

Bitcoin, digital currencies and block chain are one of the biggest opportunities of our generation: Brian Kelly    6 Mins Ago | 03:34

The fund also holds shares of Square and chipmaker Advanced Micro Devices. It has an expense ratio of 0.88 percent.

“I get asked all the time on how to invest in blockchain technology without dealing with storage, the fears of hacking, hedge funds, etc. My hope is the BKC ETF can provide this desired equity allocation to institutions and individuals alike,” Kelly said in a statement.

Bitcoin is the first application of blockchain technology, which quickly creates a permanent record of transactions between two parties and eliminates the need for a third party, such as a bank. Prices of bitcoin and other cryptocurrencies have skyrocketed in the last 18 months on increased investor interest. However, the Securities and Exchange Commission has not yet allowed a bitcoin ETF to list due to issues such as liquidity and extreme price volatility.

Four other blockchain ETFs launched in the U.S. in January: First Trust Indxx Innovative Transaction & Process ETF (LEGR), Reality Shares Nasdaq NexGen Economy ETF (BLCN), Amplify Transformational Data Sharing ETF (BLOK) and Innovation Shares NextGen Protocol ETF (KOIN).

All four funds fell single digits from the end of January to the end of March, but are up slightly for the second quarter so far.

Best Safest Stocks For 2019

Things aren’t going to script right now in the financial sector. It’s a widely established fact (based on years of historical evidence) that banks and other lenders typically prosper when interest rates are rising. In previous rate-tightening cycles, the financial sector was usually among the market’s top performers.

—Recommended Link— Create A 10%+ Income Stream For Life
We’re sitting on a collection of the safest, most generous monthly payers available. And while $11,200 in dividend checks is a welcome addition to anyone’s income, investors also love racking up capital gains as high as 446%. Start generating a 10%+ income stream for life today from these consistent companies.

As I’ve discussed before in my High-Yield Investing premium newsletter, banks can feast in these conditions because the rates they charge borrowers on loans usually rise faster than the rates they pay to depositors. That widens net interest margins (NIMs) and fattens the bottom line.

Best Safest Stocks For 2019: NIC Inc.(EGOV)

Advisors’ Opinion:

  • [By Logan Wallace]

    BidaskClub upgraded shares of NIC (NASDAQ:EGOV) from a buy rating to a strong-buy rating in a research note published on Friday morning.

    Several other research firms also recently commented on EGOV. Zacks Investment Research downgraded NIC from a hold rating to a sell rating in a report on Monday, January 8th. ValuEngine downgraded NIC from a sell rating to a strong sell rating in a report on Wednesday, May 2nd. Barrington Research restated a hold rating on shares of NIC in a report on Monday, April 30th. TheStreet downgraded NIC from a b- rating to a c rating in a report on Thursday, March 8th. Finally, Loop Capital decreased their price objective on NIC to $14.00 and set a hold rating for the company in a report on Friday, February 2nd. Two analysts have rated the stock with a sell rating, five have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $18.33.

  • [By Max Byerly]

    Shares of NIC Inc. (NASDAQ:EGOV) have earned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $18.00.

  • [By Joseph Griffin]

    Media headlines about NIC (NASDAQ:EGOV) have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. NIC earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the software maker an impact score of 44.2220263592641 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

  • [By Joseph Griffin]

    NIC Inc. (NASDAQ:EGOV) has been given a consensus recommendation of “Hold” by the ten research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $18.00.

Best Safest Stocks For 2019: Western Asset Mortgage Capital Corporation(WMC)

Advisors’ Opinion:

  • [By Max Byerly]

    ValuEngine lowered shares of Western Asset Mortgage Capit (NYSE:WMC) from a buy rating to a hold rating in a research report report published on Wednesday.

Best Safest Stocks For 2019: Aimmune Therapeutics, Inc.(AIMT)

Advisors’ Opinion:

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed most recently at $36.18, with a consensus price target of $57.38 and a 52-week range of $15.97 to $40.65.

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.13, with a consensus price target of $55.50 and a 52-week range of $15.97 to $40.65.

  • [By ]

    In the Lightning Round, Cramer was bullish on Ingersoll-Rand (IR) , The Blackstone Group (BX) , Thermo Fisher Scientific (TMO) , FMC Corp (FMC) , Nike (NKE) , Zebra Technologies (ZBRA) and Aimmune Therapeutics (AIMT) .

  • [By Chris Lange]

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) is looking for Phase 3 data for in its Palisade trial of AR101 in February. Specifically, this trial is looking to treat peanut allergies. Shares closed trading most recently at $37.20, with a consensus price target of $57.11 and a 52-week range of $15.97 to $40.65.

  • [By Shane Hupp]

    Aimmune Therapeutics (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by research analysts at Wedbush in a research report issued to clients and investors on Wednesday. They currently have a $72.00 target price on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 117.59% from the company’s previous close.

Best Safest Stocks For 2019: Infinity Pharmaceuticals, Inc.(INFI)

Advisors’ Opinion:

  • [By Logan Wallace]

    ValuEngine upgraded shares of Infinity Pharmaceuticals (NASDAQ:INFI) from a sell rating to a hold rating in a report published on Saturday morning.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Infinity Pharmaceuticals (INFI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.

Best Safest Stocks For 2019: Royal Dutch Shell PLC(RDS.A)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Royal Dutch Shell plc ADR Class A (RDS.A)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Alexander Bird]

    Much of Wall Street will tell you to stick with the oil industry giants – companies like Exxon Mobil Corp. (NYSE: XOM) or Royal Dutch Shell Plc. (NYSE: RDS.A).

What Happened in the Stock Market Today

Stocks opened lower Thursday but drifted higher during the session. TheDow Jones Industrial Average (DJINDICES:^DJI)finished a small loss and theS&P 500 (SNPINDEX:^GSPC)closed higher.

Today’s stock market

Index Percentage Change Point Change
Dow (0.03%) (7.66)
S&P 500 0.49% 13.86

Data source: Yahoo! Finance.

Technology stocks led the market, with Applemaking history by being the first U.S. company to break through $1 trillion in market capitalization. TheTechnology Select Sector SPDR ETF (NYSEMKT:XLK) gained 1.3%. The materials sector lagged; theiShares US Basic Materials ETF (NYSEMKT:IYM) fell 1%.

As for individual stocks, Sonos (UNKNOWN:UNKNOWN) rose on its first day of public trading, and Blue Apron (NYSE:APRN) tumbled following a disappointing quarterly report.

Absrtact stock graphs and prices.

Image source: Getty Images.

Sonos soars in trading debut

Sonos, maker of high-end speakers for the home audio market, traded publicly for the first time today, and shares soared 32.7% above the initial public offering price of $15. Sonos had lowered the offering price below the $17-$19 target range that was given in the registration statementit filed last week.

Sonos offered 5.6 million shares and current shareholders offered 8.3 million shares in the offering. Options on another 2.1 million shares are available to the underwriters from the company and existing shareholders. After the offering, there are a total of 98.4 million shares outstanding, giving the company a market capitalization of $2 billion. About 86% of the shares outstanding are held by current shareholders under a lock-up period for 180 days.Options for about 50 million additional shares have been issued by the company as part of its incentive plan.

The company has had success selling wireless, multiroom speaker systems known for their audio quality, and has expanded into home theater and voice-activated speakers. Revenue in 2017 was $992.5 million, a 10.1% increase from the year before, but sales appear to be accelerating, with revenue in the first two quarters of the 2018 fiscal year up 18% over the first half last year. The company is not yet profitable, with a loss of $0.25 per share last year, an improvement on a $0.71-per-share loss in 2016.

Sonos is facing some stiff competition in the speaker market from players with deep pockets, such as Apple, Amazon, and Alphabet, as well as from new entrants like Roku. Investors were ready to buy into the company’s risky proposition today, though.

Blue Apron tumbles as customer numbers shrink

Shares of meal-kit company Blue Apron got hammered today, plummeting 24.4% after the company failed to meet already-low sales expectations for the second quarter and reported that it’s losing customers at a rapid pace. Net revenue fell 25% to $180 million, compared with analyst expectations for a 21% decline. Net loss per share was $0.17, $0.01 less than the analyst consensus. The number of customers decreased 24% from the period a year earlier, and fell 9% from last quarter.

There was a little good news in the quarter, with the average orders per customer holding steady from last quarter at 4.4, and the average order value ticking up from $56.58 in Q1 to $57.34 in Q2. The cost of goods sold improved to 64.7% compared with 68.7% in Q2 last year and 65.8% in Q1 as the company made efficiency improvements. But Blue Apron had reported a sequential increase in customers last quarter, expressing optimism that momentum would continue, and that didn’t happen, with the company clearly having trouble attracting new subscribers.

Blue Apron shares had rebounded since last quarter’s report, and recently jumped on takeover rumors. But today’s news caused the stock to fall to less than a fifth of the IPO price, nearing all-time lows.

The stock market is in its 3rd-longest stretch without a new high since 2013

How long has the market been in the doldrums since scoring its most recent record? The S&P 500 index has gone about 48 trading daysnot including Fridaywithout notching a new high.

That lack of fresh highs is notable, not just because the S&P 500
SPX, -2.19%
and the Dow Jones Industrial Average
DJIA, -2.34%
are coming off an uncanny period of dormant volatility
VIX, +13.46%
and repeated all-time highs, but also because this fallow period for stocks is the third longest such span since 2013, according to Bespoke Investment Group in a Thursday note. The research and data group note that it is already the longest in about 5 years (see chart below).

The Dow and S&P 500 entered a correction phase back on Feb. 8, defined as a drop of at least 10% from a most recent peak set on Jan. 26.

Read: Why the worst may be over in the stock-market correction

If the S&P 500 goes another month, or about 20 trading days, without notching a fresh high it would surpass the period between the U.K.s market-roiling referendum to exit from out of the European Union and President Donald Trumps election, which appeared to unleashWall Streets animal spirits.

According to a report by MarketWatchs Ryan Vlastelica, since 1950, the average correction lasted for 61 trading days. That data dont include corrections that expand into a bear market, or a 20% drop from a peak.

However, Bespokes researchers are slightly more sanguine about what this current drawdown, another word for a decline in stock-market parlanceportends.

The Dow is around 9.2% lower from its late-Janua